A Phase I Study Evaluating the Efficacy and Toxicity of Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy (SBRT) in treating patients with metastatic or recurrent ovarian cancer or primary peritoneal cancer. SBRT may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- other : questionnaire administration
- procedure : positron emission tomography
- procedure : computed tomography
- radiation : stereotactic body radiation therapy
- radiation : fludeoxyglucose F 18
Phase: Phase 1
Ages Eligible For Study:
- Patients must have persistent, metastatic, or recurrent platinum resistant or refractory ovarian or primary peritoneal cancer. - No restriction on previous treatment regimens, but patients must be at least 2 weeks out from last chemotherapy or investigational agent. - Patients must be >= 18. - Patients must have a life expectancy of at least 6 months. - Patients must have KPS >= 60. - Patients must have acceptable organ and marrow function as defined below (within 2 weeks prior to radiotherapy): - leukocytes >=3,000/uL - absolute neutrophil count >=1,500uL - platelets >=100,000/uL - total bilirubin within 1.5X normal institutional limits - AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal - creatinine within normal institutional limits OR - creatinine clearance >=60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal - Patients must be willing to undergo a pre- and post-treatment FDG-PET/CT. - Ability to understand and the willingness to sign a written informed consent document.